Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib

BACKGROUND: Despite the approval of mTOR inhibitor everolimus and CDK4/6 inhibitors in the management of hormone-receptor-positive HER2 non-amplified metastatic breast cancer (HR+ HER2-MBC), the optimal sequence of therapy is unclear. There are no clinical data on efficacy of everolimus in HR+ HER2-...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhakal, Ajay, Antony Thomas, Roby, Levine, Ellis G, Brufsky, Adam, Takabe, Kazuaki, Hanna, Matthew G, Attwood, Kristopher, Miller, Austin, Khoury, Thaer, Early, Amy P, Soniwala, Saif, O’Connor, Tracy, Opyrchal, Mateusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378710/
https://www.ncbi.nlm.nih.gov/pubmed/32753876
http://dx.doi.org/10.1177/1178223420944864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378710/
https://www.ncbi.nlm.nih.gov/pubmed/32753876
http://dx.doi.org/10.1177/1178223420944864

Ejemplares similares